close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

25.99 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
17 18 Next >
News headline image
Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Analyst Ratings for ACADIA Pharmaceuticals ↗
 
Via Benzinga
News headline image
Acadia Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Analyst Ratings for ACADIA Pharmaceuticals ↗
 
Via Benzinga
News headline image
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector ↗
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
News headline image
Acadia Pharma's Rett Syndrome Drug Becomes First FDA-Approved Treatment ↗
 
Via Benzinga
News headline image
1 Top Biotech Stock to Buy in March ↗
This biotech could land a major regulatory approval this month. 
Via The Motley Fool
News headline image
Acadia Pharmaceuticals Gets Price Target Bumps By Analysts After FDA Approval Of Rett Syndrome Drug ↗
The FDA approved Acadia Pharmaceuticals Inc's (NASDAQ: ACAD) Daybue (trofinetide) for Rett syndrome in adult and pediatric patients two years of age and older. 
Via Benzinga
News headline image
Jabil To Rally Around 23%? Here Are 10 Other Analyst Forecasts For Tuesday ↗
Raymond James raised the price target for Jabil Inc. (NYSE: JBL) from $84 to $100. Raymond James analyst Melissa Fairbanks maintained a Strong Buy rating. Jabil shares fell 0.7% to close at $81.35 on... 
Via Benzinga
News headline image
Why Provention Bio Shares Are Trading Higher By Over 260%; Here Are 20 Stocks Moving Premarket ↗
Gainers Provention Bio, Inc. (NASDAQ: PRVB) rose 262.7% to $24.30 in pre-market trading after Sanofi agreed to acquire the company for $25.00 per share in cash, representing an equity value of... 
Via Benzinga
News headline image
3 Nasdaq Stocks on Watch This Week ↗
These three Nasdaq stocks are poised to make big moves in the coming week. 
Via The Motley Fool
News headline image
Looking Into ACADIA Pharmaceuticals's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Analysts See Steady Growth For Acadia Pharma's Nuplazid ↗
 
Via Benzinga
News headline image
What 10 Analyst Ratings Have To Say About ACADIA Pharmaceuticals ↗
 
Via Benzinga
News headline image
Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
ACADIA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of ACADIA Pharmaceuticals Inc. - ACAD
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Analyst Expectations for ACADIA Pharmaceuticals's Future ↗
 
Via Benzinga
News headline image
Mizuho Maintains Neutral Rating for ACADIA Pharmaceuticals: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 27, 2023 ↗
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million. 
Via Benzinga
News headline image
Earnings Preview For ACADIA Pharmaceuticals ↗
 
Via Benzinga
News headline image
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and Development
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinson’s Disease Psychosis Patients Treated with NUPLAZID® (pimavanserin) Compared to Those Treated with Other Atypical Antipsychotics
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
ACADIA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ACADIA Pharmaceuticals Inc. - ACAD
From Kahn Swick & Foti, LLC
Via Business Wire
Acadia Trofinetide Phase III Clinical Top-Line Results Positive
Via AB Newswire
News headline image
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022 ↗
Upgrades 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today